NUVL News and Press, Nuvalent Inc. From 05/16/24

2024-05-16 16:18:34 ET More on Nuvalent Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024 Jefferies starts Nuvalent at buy, cites lung cancer drug candidates Nuvalent lung cancer candidate gets FDA breakthrough therapy status Seeking A...

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 PR Newswire CAMBRIDGE, Mass. , May 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therap...

2024-05-09 10:59:16 ET More on Nuvalent Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024 Jefferies starts Nuvalent at buy, cites lung cancer drug candidates Nuvalent lung cancer candidate gets FDA breakthrough therapy status Read th...

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results PR Newswire Updates from the ongoing Phase 1/2 ARROS-1 and ALKOVE-1 clinical trials expected at a medical meeting in the second half of 2024 S...

2024-04-18 09:54:06 ET More on Nuvalent Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024 Nuvalent lung cancer candidate gets FDA breakthrough therapy status Baird starts Nuvalent at outperform, cites potential of lead assets Seeking A...

2024-04-13 13:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 PR Newswire Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations...

2024-03-24 14:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 PR Newswire CAMBRIDGE, Mass. , March 5, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biophar...